Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Statera Biopharma News

    0,0007 $ 0,00% +0,00 $
    In : 0,0007 € | 29.04.24 17:37:36 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3C2CC
    ISIN: US8575611046
    US-Symbol: STAB
    Typ: Aktie

    Statera Biopharma News

    09.09.22 - ACCESSWIRE
    Statera Biopharma Receives Nasdaq Listing Determination; Hearing Requested to Address Filing Delinquency
    FORT COLLINS, CO / ACCESSWIRE / September 9, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating ...
    25.08.22 - ACCESSWIRE
    Statera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from Nasdaq
    FORT COLLINS, CO / ACCESSWIRE / August 25, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating ...
    29.04.22 - PR Newswire
    Thinking about buying stock in Fangdd Network Group, Statera Biopharma, Borqs Technologies, Accolade, or Arrival?
    Thinking about buying stock in Fangdd Network Group, Statera Biopharma, Borqs Technologies, Accolade, or Arrival? PR Newswire
    28.04.22 - PR Newswire
    Thinking about buying stock in Statera Biopharma, Nokia, Borqs Technologies, Clarus Therapeutics, or Blend Labs?
    Thinking about buying stock in Statera Biopharma, Nokia, Borqs Technologies, Clarus Therapeutics, or Blend Labs? PR Newswire
    13.04.22 - PR Newswire
    Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma
    Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-​Stage Asset Entolimod, from Statera Biopharma PR Newswire
    22.09.21 - PR Newswire
    Statera Biopharma, Inc. to Participate in the Benzinga Healthcare Small Cap Conference
    Statera Biopharma, Inc. to Participate in the Benzinga Healthcare Small Cap Conference PR Newswire
    21.09.21 - PR Newswire
    Statera Biopharma, Inc. to Participate in the Cantor Virtual Global Healthcare Conference
    Statera Biopharma, Inc. to Participate in the Cantor Virtual Global Healthcare Conference PR Newswire
    09.09.21 - PR Newswire
    Statera BioPharma, Inc. to Ring Nasdaq Stock Market Closing Bell
    Statera BioPharma, Inc. to Ring Nasdaq Stock Market Closing Bell PR Newswire
    16.08.21 - PR Newswire
    Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast
    Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast Audio archive for the event may be accessed from the "Investors" section of the ...
    16.08.21 - PR Newswire
    Cytocom, Inc. Reports Second Quarter 2021 Financial Results
    Cytocom, Inc. Reports Second Quarter 2021 Financial Results -All-​stock merger transaction between legacy Cleveland BioLabs and legacy Cytocom recently completed; Cytocom, ...
    12.08.21 - PR Newswire
    Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement
    Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement Cytocom to fund research in cancer, autoimmune and inflammatory ...
    11.08.21 - PR Newswire
    Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
    Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference Mike K. Handley, President and CEO, will participate as ...
    09.08.21 - PR Newswire
    Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
    Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19 Patient enrollment in Phase 3 pediatric Crohn's ...
    05.08.21 - PR Newswire
    Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs
    Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs PR Newswire
    29.07.21 - PR Newswire
    Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing
    Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing Financing Led by GEM Global Yield LLC SCS, and Joined by Avenue Capital, and Adit Ventures ...
    06.07.21 - PR Newswire
    Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger
    Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger Special Investor Call will be held Wednesday, July 7, at ...
    17.06.21 - PR Newswire
    Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC
    Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC Special Stockholders ...
    14.04.21 - ACCESSWIRE
    Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532
    The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals
    09.04.21 - PR Newswire
    SHAREHOLDER ALERT: WeissLaw LLP Reminds MDCA, PTVCA, CBLI, and WIFI Shareholders About Its Ongoing Investigations
    SHAREHOLDER ALERT: WeissLaw LLP Reminds MDCA, PTVCA, CBLI, and WIFI Shareholders About Its Ongoing Investigations PR Newswire
    02.04.21 - PR Newswire
    SHAREHOLDER ALERT: WeissLaw LLP Reminds MDCA, FFG, PTVCA, and CBLI Shareholders About Its Ongoing Investigations
    SHAREHOLDER ALERT: WeissLaw LLP Reminds MDCA, FFG, PTVCA, and CBLI Shareholders About Its Ongoing Investigations PR Newswire

    Newssuche

    Videos

    newspaper
    30.04.24 -9,41%
    Technical Trading: Sojabohnen Long bis Juli
    Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »